C-reactive protein and glucose regulation in familial longevity by Rozing, Maarten P. et al.
C-reactive protein and glucose regulation
in familial longevity
Maarten P. Rozing & Simon P. Mooijaart & Marian Beekman &
Carolien A. Wijsman & Andrea B. Maier & Andrzej Bartke &
Rudi G.J. Westendorp & Eline P. Slagboom & Diana van Heemst
Received: 24 August 2010 /Accepted: 3 January 2011 /Published online: 19 January 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Earlier, we showed that the offspring from
exceptionally long-lived families have a more favor-
able glucose metabolism when compared with con-
trols. As chronic low-grade inflammation has been
regarded as a strong risk factor for insulin resistance,
we evaluated if and to what extent the favorable
glucose metabolism in offspring from long-lived
families could be explained by differences in subclin-
ical inflammation, as estimated from circulating levels
of C-reactive protein. We found no difference
between the two groups in C-reactive protein levels
or in the distribution of C-reactive protein haplotypes.
However, among controls higher levels of C-reactive
protein were related to higher glucose levels, whereas
among offspring levels of C-reactive protein were
unrelated to glucose levels. It is a limitation of the
current study that its cross-sectional nature does not
allow for assessment of cause–effect relationships.
One possible interpretation of these data is that the
offspring from long-lived families might be able to
regulate glucose levels more tightly under conditions
of low-grade inflammation. To test this hypothesis,
our future research will be focused on assessing the
robustness of insulin sensitivity in response to various
challenges in offspring from long-lived families and
controls.
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Introduction
The association between chronic subclinical inflam-
mation and insulin resistance has been well estab-
lished (Shoelson et al. 2006). Insulin resistance in turn
is regarded a strong risk factor for type 2 diabetes,
hypertension, and cardiovascular disease (Mcfarlane
et al. 2001; Shen et al. 1988). Levels of C-reactive
protein (CRP), a marker of systemic inflammation,
are elevated in subjects with impaired glucose
tolerance as well as in overt diabetes (Ford 1999;
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levels of CRP are predictive for development of
diabetes (Barzilay et al. 2001; Pradhan et al. 2001).
Observational studies have shown a relation between
elevated levels of CRP and elevated glucose levels in
subjects without diabetes as well (Doi et al. 2005;
Festa et al. 2002; Nakanishi et al. 2005).
In the Leiden Longevity Study, we have recruited
exceptionally long-lived families based on proband
siblings that both exhibit exceptional longevity. We
also included the middle-aged offspring of the long-
lived siblings and their partners as population-based
controls. Earlier, we have shown that the offspring
from these long-lived families have a lower preva-
lence of type 2 diabetes when compared with controls
(Westendorp et al. 2009). Moreover, we demonstrated
that after exclusion of diabetic patients the offspring
from long-lived families had relatively lower fasted
and non-fasted glucose levels as well as a higher
glucose tolerance (Rozing et al. 2009; Rozing et al.
2010). The differences in glucose metabolism be-
tween offspring from long-lived families and controls
could not be explained by differences in body
composition or life style, such as smoking or physical
activity.
In the current study, we sought to evaluate whether
and to what extent the observed differences in glucose
metabolism between the offspring from long-lived
families and controls can be explained by differences
in subclinical inflammation, as estimated from circu-
lating levels of CRP. Therefore, we examined high-
sensitivity C-reactive protein (hsCRP) serum levels as
well as CRP genotypes and their influence on glucose
regulation in the offspring from exceptionally long-
lived families and controls.
Materials and methods
The Leiden Longevity Study
The recruitment of 421 families in the Leiden
Longevity Study has been described before (Schoen-
maker et al. 2006). A short outline is provided here.
Families were recruited if at least two long-lived
siblings were alive and fulfilled the age criterion of
89 years or older for males and 91 years or older for
females. There were no selection criteria on health or
demographic characteristics. For 2,415 offspring of
long-lived siblings and their partners as population
controls, non-fasting serum samples were taken at
baseline for the determination of endocrine and
metabolic parameters. Additional information was
collected from the generation of offspring and con-
trols, including self-reported information on life style,
information on medical history from the participants’
treating physicians, and information on medication
use from the participants’ pharmacists. Subjects with
hsCRP levels higher than 10.0 mg/L were excluded
from the study (68 offspring (4.6%) and 31 controls
(4.9%)) as were subjects with diabetes (65 offspring
(4.4%) and 53 controls (8.3%)). Subjects were
regarded as having diabetes if they had non-fasted
glucose levels >11.0 mmol/L, a previous medical
history of diabetes and/or used glucose lowering
agents. In 84 subjects (61 offspring and 23 controls),
data on hsCRP and/or glucose were not available.
CRP genotypes
Three single-nucleotide polymorphisms (SNPs) were
selected that associate with serum CRP levels: rs1205
(positioned in 3′UTR, alleles C/T), Rs1800947
(positioned in Codon 184, alleles G/C) and
Rs1417938 (positioned in intron 1, alleles T/A).
Genotyping of the SNPs was performed using
Sequenom MassARRAY iPLEX
®Gold. The high
iPLEX primer design was performed by entering the
sequences encompassing each polymorphism into
SpectroDESIGNER provided by Sequenom®, Inc.
(CA, USA). The high plex reaction protocol was
used (www.sequenom.com/iplex). The average geno-
type call rate for genotyped SNPs was 96.3%, and the
average concordance rate was 99.7% among 4%
duplicated control samples. All SNPs were in Hardy–
Weinberg equilibrium (p≥0.05)
Plasma parameters
All serum measurements were performed with fully
automated equipment. Insulin was measured on the
Immulite 2500 Analyzer from Diagnostic Products
Corporation (Los Angeles, CA, USA) using a solid-
phase, enzyme-labeled chemiluminescent immunomet-
ric assay, according to the instructions of the manufac-
turer. For glucose and hsCRP, the Hitachi Modular P
800 from Roche, Almere, the Netherlands was applied.
CV’s of all measurements were below 5%.
624 AGE (2011) 33:623–630Statistical analysis
The program haploview was used to estimate allele
frequencies, test the consistency of genotype frequen-
cies at each SNP locus with Hardy–Weinberg equi-
librium and estimate and plot pair wise LD between
the examined SNPs. Haplotypes and haplotype
frequencies were estimated using the SNPHAP
software. The posterior probabilities of haplotypes
<95% were excluded from the analyses (61 offspring
and 24 controls).
Distributions of continuous variables were exam-
ined for normality and serum insulin levels and
hsCRP levels were logarithmically transformed prior
to analyses. Differences in age between the groups of
offspring and controls were tested using a Mann–
Whitney rank sum test. Differences in sex distribution
between the groups of offspring and controls were
calculated using a Chi-square test. Geometric means
(with 95% confidence intervals) are reported for
transformed variables. Associations between serum
levels as well as associations between CRP haplo-
types and serum levels were tested using a linear
mixed model with a random sibship effect to model
correlation of sibling data. Age, sex, body mass
index, use of lipid-lowering agents, and current
smoking were regarded as potential confounders in
this association and were included in the analyses.
The Statistical Package for the Social Sciences
program for Windows, version 16.0 was used for
data analysis.
Results
The principal features of the study groups, both
without diabetes, are displayed in Table 1.T h e
proportion of males was slightly higher in the group
of offspring than in the group of controls. Body mass
index was similar between the two groups (p=0.57).
Non-fasted glucose levels were lower in the group of
offspring when compared with the group of controls
(p=0.001), while non-fasted insulin levels did not
differ (p=0.16). We did not observe a difference in
serum levels of hsCRP between the two groups. Also
after adjustment for the potential confounders age,
sex, body mass index, use of lipid-lowering agents,
and current smoking, no difference in hsCRP levels
was observed between the two groups (Table 1).
Potentially, genetic variation could mask true
differences in CRP levels between the two groups.
To distinguish between constitutional and acquired
levels of hsCRP, we performed a genetic analysis of
haplotypes constructed from the common CRP variants
rs1205, rs1800947, and rs1417938 that have previ-
ously been associated with serum CRP levels. For the
present analyses we report the results of the four most
common haplotypes (frequency >5%) that cumulative-
ly account for 99.9% of the haplotypes. The relation
between the four selected haplotypes and serum
hsCRP levels is depicted in Table 2. All haplotypes
correlated significantly with hsCRP levels. An increas-
ing number of haplotypes 1 and 2 gave rise to higher
hsCRP levels, whereas an increasing number of
haplotypes 3 and 4 was related to a decrease in hsCRP
serum levels. The change in hsCRP levels over the
number of haplotypes was not different between
offspring and controls.
Next, we assessed if the distribution of CRP
haplotypes was different between the two groups.
In both the study groups haplotypes were in
Hardy–Weinberg equilibrium. No difference in the
frequencies of CRP haplotypes was observed
between the group of offspring and the group of
controls (Table 3).
Since high levels of CRP have been associated
with insulin resistance, we examined the association
between serum levels of hsCRP and serum levels of
non-fasted insulin as well as glucose for the group of
offspring and the group of controls. Distributions of
continuous variables were examined for normality
and serum insulin levels and hsCRP levels were
logarithmically transformed prior to analyses. Higher
levels of hsCRP were consistently related to higher
levels of insulin in both groups (Fig. 1a). In the group
of offspring, one standard deviation increase in
logarithmically transformed hsCRP (ln hsCRP) was
associated with an increase in levels of logarithmi-
cally transformed insulin (ln insulin) of 0.08 (95%
confidence interval, 0.04–0.13) μ IU/L (p<0.001).
In the group of controls, one standard deviation
increase in ln hsCRP was associated with an
increase in levels of ln serum insulin of 0.11
(95% confidence interval, 0.04–0.19) μ IU/L (p=
0.004). The relation between hsCRP and insulin
was not different between the two groups (p value
for interaction=0.28). Next, we examined the
relation between hsCRP and glucose in the two
AGE (2011) 33:623–630 625groups. Among offspring no significant relation
was observed between one standard deviation
increase in ln hsCRP and glucose (mmol/L): 0.01
(−0.05 to 0.08; p=0.71)(Fig.1b). In contrast among
controls, one standard deviation increase in ln
hsCRP was related with a 0.13 (0.02–0.24) mmol/L
increase in serum glucose levels (p=0.017). The
association between hsCRP and glucose was signif-
icantly different in the group of controls when
compared with the group of offspring (p value for
interaction=0.020).
If CRP haplotypes associate with CRP levels and
CRP levels associate with markers of glucose
metabolism, it could be expected that CRP hap-
lotypes associate with markers of glucose metabo-
lism. To tease out the causal relation between
serum hsCRP and glucose metabolism we assessed
the relationship between CRP haplotypes and serum
levels of insulin as well as glucose (Table 4). In
both groups, none of the haplotypes demonstrated an
association with levels of serum insulin nor serum
glucose.
Table 1 Baseline characteristics of the study population
Offspring Controls p value
Participants (N) 1,479 635
Male sex (N, %) 691 (46.7) 264 (41.6) 0.032
Age in year (median (interquartile range)) 59.1 (54.9–64.0) 58.7 (53.8–63.6) 0.078
Body mass index in kg/m
2 (mean, 95% CI)
a 25.3 (25.0–25.5) 25.4 (25.1–25.7) 0.57
Lipid-lowering agent (N, %) 87 (5.9) 45 (7.1) 0.33
Currently smoking 167 (13.2) 78 (14.0) 0.66
Insulin in μ IU/L (mean, 95% CI) 15.7 (14.9–16.4) 16.6 (15.5–17.7) 0.16
Glucose in mmol/L (mean, 95% CI) 5.70 (5.64–5.77) 5.90 (5.81–5.99) 0.001
HsCRP in mg/dL (mean, 95% CI)
Adjusted for sex and age (model 1) 1.21 (1.15–1.28) 1.25 (1.16{1.34) 0.54
Model 1 and body mass index 1.20 (1.32–1.26) 1.23 (1.15–1.32) 0.56
Model 1 and lipid-lowering agents 1.06 (0.97–1.16) 1.10 (1.00–1.21) 0.48
Model 1 and current smoking status
b 1.30 (1.21–1.40) 1.34 (1.23–1.46) 0.53
Model 1 and body mass index and lipid-lowering agents and current smoking status 1.11 (1.01–1.23) 1.14 (1.03–1.26) 0.54
Results for insulin and hsC-reactive protein (hsCRP) are presented as estimated geometric means with 95% confidence intervals
95% CI 95% confidence interval
aData on body mass were available for 1,823 subjects (1,266 offspring and 557 partners). Results for body mass index were adjusted
for age and sex
bData on current smoking status were available for 1,819 subjects (1,262 offspring and 557 partners). Results for insulin and glucose
were adjusted for age, sex, and body mass index
Table 2 Association between CRP haplotypes and serum hsCRP levels
Haplotype 0 copies (mean (95% CI)) 1 copy (mean (95% CI)) 2 copies (mean (95% CI)) p value for trend p value for interaction
HsCRP (mg/dL)
1 1.17 (1.09–1.24) 1.25 (1.18–1.34) 1.35 (1.20–1.51) 0.015 0.87
2 1.13 (1.06–1.20) 1.28 (1.20–1.36) 1.45 (1.28–1.65) <0.001 0.63
3 1.32 (1.24–1.40) 1.14 (1.07–1.22) 1.04 (0.89–1.22) <0.001 0.18
4 1.27 (1.21–1.34) 0.97 (0.87–1.09) 0.52 (0.29–0.93) <0.001 0.23
Results for serum high-sensitivity C-reactive protein (hsCRP) are given as estimated geometric means and 95% confidence intervals
for number of haplotypes. Results were adjusted for sex, age, and study group (controls and offspring). p value for interaction was
calculated for the difference between controls and offspring in the trend of hsCRP over increasing number of haplotypes
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Earlier it has been demonstrated that the offspring
from exceptionally long-lived families have a more
favorable glucose metabolism when compared with
population-based controls (Rozing et al. 2009; Rozing
et al. 2010). In the present study, we show that this
difference in glucose metabolism could not be
explained by current differences in subclinical inflam-
mation, as estimated from serum levels of hsCRP. We
did not find a difference in the levels of hsCRP
between the group of offspring from long-lived
families and the group of environmentally matched
controls, nor in the frequencies of common genetic
CRP variants and haplotypes. All CRP haplotypes
correlated significantly with hsCRP levels, however
no association was found between CRP haplotypes
and insulin or glucose levels. We observed a distinct
association between levels of hsCRP and levels of
glucose in the two groups: in the group of controls
increasing levels of hsCRP were associated with
higher non-fasted glucose levels, whereas in the
group of offspring this relation was absent.
The regulation of CRP levels via the paracrine
effects of adipokines is well understood and the lack
of difference between the group of offspring and
controls in hsCRP levels is in line with our earlier
observation that there were no significant differences
in percentage of body fat or BMI between the groups
(Rozing et al. 2010). Despite the absence of differ-
ences in BMI or percentage of body fat, we earlier
observed a lower prevalence of metabolic syndrome
in the subgroups of offspring compared with controls
for which data on metabolic syndrome were available
(Rozing et al. 2010) The metabolic syndrome is a
combination of cardiovascular risk factors for which
the dominant underlying factor appears to be insulin
resistance (Hanley et al. 2002). A chronic subclinical
inflammatory state is considered a crucial factor in
the development of insulin resistance (Temelkova-
Kurktschiev et al. 2002;S p r a n g e re ta l .2003). In
accordance, insulin resistance has been shown to
correspond closely with elevated levels of inflamma-
tory markers as CRP (Festa et al. 2000; Yudkin et al.
1999). It is a limitation of the current study that its
cross-sectional nature does not allow for assessment of
Fig. 1 Association between hsCRP levels and non-fasted
serum insulin levels (a) and serum glucose levels (b) for
offspring and controls. HsCRP levels were dichotomized into
categories of low and high hsCRP levels based on the median
value of hsCRP of the whole population (1.15 mg/dL). The
analyses were adjusted for sex, age, lipid-lowering agents,
BMI, and current smoking status. *p value lower than 0.05
SNP allele Frequency
Haplotype rs1205 rs1800947 rs1417938 Offspring Controls p value
1 T G T 0.335 0.344 0.57
2T GA 0.336 0.315 0.17
3 C G T 0.260 0.273 0.38
4 CC T 0.069 0.068 0.94
Table 3 CRP haplotype
structure and frequencies
Minor alleles are set in
italics
SNP single-nucleotide
polymorphism
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of the current observation that the difference in glucose
levels reported earlier for offspring of long-lived
families compared with controls is mostly manifested
in the presence of high levels of the inflammatory
marker CRP is that the offspring from long-lived
families might be able to regulate glucose levels
more tightly under conditions of low-grade inflam-
mation. According to this hypothesis, subjects from
long-lived families would be protected by their
robust insulin sensitivity against the effects of low-
grade inflammation and concomitant morbidity,
such as for example metabolic syndrome. Alterna-
tively, CRP or other factors associated with high
CRP levels might be causal in the observed
difference in glucose levels between groups in the
presence of high CRP levels.
During inflammation, acute-phase reactants and
pro-inflammatory cytokines are thought to induce a
hypermetabolic state. This hypermetabolic state,
which is aimed at mobilizing energy to support
immune function and tissue repair, is characterized
by an accelerated gluconeogenesis (Mizock 1995)a s
well as induced insulin resistance resulting in elevated
glucose levels (Taniguchi et al. 2006)( F i g .2a).
Preserved insulin action in the offspring may allow
for disposal of the excess glucose and/or reduced
hepatic gluconeogenesis, thereby abolishing the in-
flammatory induced hyperglycemia (Fig. 2b). Hypo-
thetically, a favorable balance between insulin-
sensitizing and diabetogenic components underlies
this phenomenon. Multiple endogenous diabetogenic
components and insulin-sensitizing factors have been
identified, as for example IL-6, TNF-α, PAI-1, and
Table 4 Association between CRP haplotypes and serum glucose parameters
Haplotype 0 copies (mean (95% CI)) 1 copy (mean (95% CI)) 2 copies (mean (95% CI)) p valuefor trend p value for interaction
Serum insulin (μ IU/L)
1 16.1 (15.2–17.1) 16.2 (15.3–17.2) 16.9 (15.2–18.7) 0.54 0.68
2 16.4 (15.5–17.4) 16.0 (15.1–17.0) 16.6 (14.8–18.7) 0.84 0.15
3 16.4 (15.5–17.2) 16.5 (15.5–17.5) 14.4 (12.4–16.6) 0.09 0.23
4 16.1 (15.5–16.9) 17.3 (15.6–19.2) 11.9 (6.57–21.6) 0.41 0.83
Serum glucose (mmol/L)
1 5.80 (5.72–5.87) 5.82 (5.74–5.89) 5.83 (5.68–5.97) 0.66 0.49
2 5.80 (5.73–5.88) 5.79 (5.71–5.87) 5.92 (5.76–6.07) 0.42 0.39
3 5.84 (5.77–5.91) 5.79 (5.71–5.87) 5.65 (5.46–5.85) 0.09 0.40
4 5.80 (5.74–5.86) 5.88 (5.74–6.02) 5.39 (4.67–6.11) 0.57 0.18
Results for serum insulin are given as estimated geometric means and 95% confidence intervals for number of haplotypes. Results for
glucose are given as estimated means and 95% confidence intervals for number of haplotypes. Results were adjusted for sex, age, and
study group (controls and offspring). p value for interaction was calculated for the difference between controls and offspring in the
trend of insulin or glucose over increasing number of haplotypes
Fig. 2 Mechanism of inflammatory induced hyperglycemia. The
inflammatory state is characterized by an accelerated hepatic
gluconeogenesis as well as induced peripheral insulin resistance
leading to hyperglycemia (a). Preserved insulin action in the
offspring from long-lived families presumably allows for disposal
of excess glucose and/or reduced hepatic gluconeogenesis,
thereby abolishing the inflammatory induced hyperglycemia (b)
628 AGE (2011) 33:623–630leptin on the one hand, and adiponectin on the other
hand (Arai et al. 2009). Our future research will focus
on unraveling the specific mechanisms of the robust
glucose metabolism in offspring from long-lived
families.
The absence of fasted samples has precluded
homeostasis model assessment of insulin resistance.
The absence of fasted samples for this relatively large
cohort of the Leiden Longevity Study is a limitation of
the current study. However, although uncontrolled, non-
fasted samples reflect everyday variations in circulating
concentration of insulin and glucose and may allow for
detection of differences in glucose handling between
groups across a physiologically relevant spectrum of
insulin and glucose concentrations.
In conclusion, we found that the difference in non-
fasted glucose levels reported earlier between groups
of offspring from long-lived families and controls is
most pronounced in the presence of high levels of the
inflammatory marker CRP. It is a limitation of the
current study that its cross-sectional nature does not
allow for assessment of cause–effect relationships.
However, one possible interpretation of this observa-
tion is that, compared with controls, offspring from
long-lived families might be able to regulate glucose
levels more tightly under conditions of low-grade
inflammation.
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